Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Centessa Pharmaceuticals Plc ADR
(NQ:
CNTA
)
13.17
+0.13 (+1.00%)
Streaming Delayed Price
Updated: 9:50 AM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Centessa Pharmaceuticals Plc ADR
< Previous
1
2
3
Next >
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
March 27, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines
March 01, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Plc (NASDAQ:CNTA) Long Term Shareholder Notice: Investigation of Potential Wrongdoing
February 14, 2023
San Diego, CA -- (SBWIRE) -- 02/14/2023 -- An investigation was announced for investors in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) concerning potential breaches of fiduciary duties by...
Via
SBWire
Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
February 06, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
NASDAQ: CNTA Investor Alert: Deadline on November 28, 2022 in Lawsuit against Centessa Pharmaceuticals plc
November 28, 2022
San Diego, CA -- (SBWIRE) -- 11/28/2022 --
Via
SBWire
Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference
February 02, 2023
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
January 26, 2023
LB101 is a conditionally tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody being developed for solid tumors
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
December 10, 2022
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson
November 30, 2022
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Reminds Centessa Pharmaceuticals plc (CNTA) Investors of Class Action Deadline and Encourages Investors to Actively Participate
November 28, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
November 27, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
CENTESSA PHARMACEUTICALS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess Of $100,000 of Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTA
November 25, 2022
From
Kahn Swick & Foti, LLC
Via
Business Wire
CENTESSA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Centessa Pharmaceuticals Plc and Encourages Investors to Contact the Firm
November 25, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
November 21, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
November 16, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm
November 11, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022
November 10, 2022
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm
November 06, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting
November 03, 2022
New efficacy and safety data from 18-months of continued treatment with subcutaneous doses of SerpinPC in subjects with hemophilia accepted for oral presentation
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm
October 31, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
October 31, 2022
From
Centessa Pharmaceuticals plc
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Warner Bros., Olo, Centessa, and PayPal and Encourages Investors to Contact the Firm
October 26, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Barclays, Warner Bros., Olo, and Centessa and Encourages Investors to Contact the Firm
October 21, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Centessa, PayPal, Opendoor, and Schmitt and Encourages Investors to Contact the Firm
October 16, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC, A Top Firm, Notifies Centessa Pharmaceuticals plc (CNTA) Investors of Class Action and Encourages Investors to Actively Participate
October 13, 2022
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
NASDAQ:CNTA Shareholder Notice: Lawsuit Alleges Securities Laws Violations by Centessa Pharmaceuticals Plc
October 12, 2022
San Diego, CA -- (SBWIRE) -- 10/12/2022 -- An investor, who purchased shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA), filed a lawsuit against Centessa Pharmaceuticals plc over alleged Federal...
Via
SBWire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Centessa, PayPal, Opendoor, and Schmitt and Encourages Investors to Contact the Firm
October 11, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Centessa and PayPal and Encourages Investors to Contact the Firm
October 06, 2022
From
Bragar Eagel & Squire
Via
GlobeNewswire
Centessa Pharmaceuticals Plc (NASDAQ:CNTA) Investor Alert: Investigation over Potential Wrongdoing
October 05, 2022
San Diego, CA -- (SBWIRE) -- 10/05/2022 -- An investigation on behalf of investors in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) was announced over potential breaches of fiduciary duties by...
Via
SBWire
INVESTOR NOTICE: Centessa Pharmaceuticals plc Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – CNTA
October 03, 2022
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.